Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Apr;49(4):338–342. doi: 10.1136/jcp.49.4.338

Cell growth and p53 expression in primary acquired melanosis and conjunctival melanoma.

S Seregard 1
PMCID: PMC500463  PMID: 8655713

Abstract

AIMS: To evaluate cell growth and the pattern of p53 suppressor gene expression in atypical primary acquired melanosis (PAM) and in recurrent conjunctival melanoma. METHODS: Eighteen specimens of PAM with atypia and 24 specimens, comprising early and late lesions, from 12 patients with conjunctival melanoma were stained for the proliferating cell nuclear antigen using the PC10 antibody, and for the p53 gene product using the BP53-12-1, 1801 and DO7 clones. The immunoreactive cells were counted manually and the data evaluated statistically. RESULTS: Seven of nine PAM specimens progressing to melanoma expressed PC10. None of these lesions expressed the p53 gene product. The number of proliferating cells was higher in the late than in the early lesions of conjunctival melanoma. Four of the 12 recurrent melanomas displayed focal, but minimal, p53 expression. The proliferating cell count in the p53 positive tumours was very similar to that of the p53 negative conjunctival melanomas. CONCLUSION: Examination of the expression of proliferating cells in atypical PAM may be used as an adjunct to predict which lesions will progress to melanoma. The increase in the number of proliferating cells over time in recurrent conjunctival melanomas probably reflects more aggressive behaviour and may be used to monitor recurrence. The absence of p53 expression in PAM and minimal staining of conjunctival melanomas did not correlate with cell growth, suggesting that alterations in the p53 tumour suppressor gene are uncommon and late events in conjunctival melanoma, and that p53 expression is unlikely to be a useful prognostic indicator.

Full text

PDF
338

Images in this article

339Image
on p.339
340Image
on p.340

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akslen L. A., Mørkve O. Expression of p53 protein in cutaneous melanoma. Int J Cancer. 1992 Aug 19;52(1):13–16. doi: 10.1002/ijc.2910520104. [DOI] [PubMed] [Google Scholar]
  2. Baker S. J., Fearon E. R., Nigro J. M., Hamilton S. R., Preisinger A. C., Jessup J. M., vanTuinen P., Ledbetter D. H., Barker D. F., Nakamura Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989 Apr 14;244(4901):217–221. doi: 10.1126/science.2649981. [DOI] [PubMed] [Google Scholar]
  3. Barbareschi M., Iuzzolino P., Pennella A., Allegranza A., Arrigoni G., Dalla Palma P., Doglioni C. p53 protein expression in central nervous system neoplasms. J Clin Pathol. 1992 Jul;45(7):583–586. doi: 10.1136/jcp.45.7.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cordon-Cardo C., Dalbagni G., Saez G. T., Oliva M. R., Zhang Z. F., Rosai J., Reuter V. E., Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer. 1994 Feb 1;56(3):347–353. doi: 10.1002/ijc.2910560309. [DOI] [PubMed] [Google Scholar]
  5. De Potter P., Shields C. L., Shields J. A., Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993 Oct;77(10):624–630. doi: 10.1136/bjo.77.10.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Esrig D., Spruck C. H., 3rd, Nichols P. W., Chaiwun B., Steven K., Groshen S., Chen S. C., Skinner D. G., Jones P. A., Cote R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993 Nov;143(5):1389–1397. [PMC free article] [PubMed] [Google Scholar]
  7. Folberg R., McLean I. W., Zimmerman L. E. Conjunctival melanosis and melanoma. Ophthalmology. 1984 Jun;91(6):673–678. doi: 10.1016/s0161-6420(84)34245-2. [DOI] [PubMed] [Google Scholar]
  8. Folberg R., McLean I. W., Zimmerman L. E. Primary acquired melanosis of the conjunctiva. Hum Pathol. 1985 Feb;16(2):129–135. doi: 10.1016/s0046-8177(85)80061-7. [DOI] [PubMed] [Google Scholar]
  9. Greenwell A., Foley J. F., Maronpot R. R. An enhancement method for immunohistochemical staining of proliferating cell nuclear antigen in archival rodent tissues. Cancer Lett. 1991 Sep;59(3):251–256. doi: 10.1016/0304-3835(91)90149-c. [DOI] [PubMed] [Google Scholar]
  10. Haerslev T., Jacobsen G. K. Microwave processing for immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) in formalin-fixed and paraffin-embedded tissue. APMIS. 1994 May;102(5):395–400. doi: 10.1111/j.1699-0463.1994.tb04889.x. [DOI] [PubMed] [Google Scholar]
  11. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  12. Jay M., McCartney A. C. Familial malignant melanoma of the uvea and p53: a Victorian detective story. Surv Ophthalmol. 1993 May-Jun;37(6):457–462. doi: 10.1016/0039-6257(93)90142-t. [DOI] [PubMed] [Google Scholar]
  13. Kennedy S. M., Macgeogh C., Jaffe R., Spurr N. K. Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol. 1994 May;25(5):438–442. doi: 10.1016/0046-8177(94)90114-7. [DOI] [PubMed] [Google Scholar]
  14. Korkolopoulou P., Oates J., Crocker J., Edwards C. p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen. J Clin Pathol. 1993 Dec;46(12):1093–1096. doi: 10.1136/jcp.46.12.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Landberg G., Roos G. Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis. Cancer Res. 1991 Sep 1;51(17):4570–4574. [PubMed] [Google Scholar]
  16. Lassam N. J., From L., Kahn H. J. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res. 1993 May 15;53(10 Suppl):2235–2238. [PubMed] [Google Scholar]
  17. Leong A. S., Milios J., Duncis C. G. Antigen preservation in microwave-irradiated tissues: a comparison with formaldehyde fixation. J Pathol. 1988 Dec;156(4):275–282. doi: 10.1002/path.1711560402. [DOI] [PubMed] [Google Scholar]
  18. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  19. Levine A. J., Momand J. Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta. 1990 Jun 1;1032(1):119–136. doi: 10.1016/0304-419x(90)90015-s. [DOI] [PubMed] [Google Scholar]
  20. Matias-Guiu X., Cuatrecasas M., Musulen E., Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol. 1994 Apr;47(4):337–339. doi: 10.1136/jcp.47.4.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McGregor J. M., Yu C. C., Dublin E. A., Barnes D. M., Levison D. A., MacDonald D. M. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol. 1993 Jun;128(6):606–611. doi: 10.1111/j.1365-2133.1993.tb00253.x. [DOI] [PubMed] [Google Scholar]
  22. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989 Dec 7;342(6250):705–708. doi: 10.1038/342705a0. [DOI] [PubMed] [Google Scholar]
  23. Paridaens A. D., McCartney A. C., Minassian D. C., Hungerford J. L. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol. 1994 Jul;78(7):520–528. doi: 10.1136/bjo.78.7.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Platz A., Ringborg U., Grafström E., Hög A., Lagerlöf B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res. 1995 Apr;5(2):101–106. doi: 10.1097/00008390-199504000-00005. [DOI] [PubMed] [Google Scholar]
  25. Poller D. N., Roberts E. C., Bell J. A., Elston C. W., Blamey R. W., Ellis I. O. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol. 1993 May;24(5):463–468. doi: 10.1016/0046-8177(93)90157-c. [DOI] [PubMed] [Google Scholar]
  26. Sasano H., Miyazaki S., Gooukon Y., Nishihira T., Sawai T., Nagura H. Expression of p53 in human esophageal carcinoma: an immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol. 1992 Nov;23(11):1238–1243. doi: 10.1016/0046-8177(92)90291-a. [DOI] [PubMed] [Google Scholar]
  27. Scarpa A., Capelli P., Mukai K., Zamboni G., Oda T., Iacono C., Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol. 1993 May;142(5):1534–1543. [PMC free article] [PubMed] [Google Scholar]
  28. Seregard S., Kock E. Conjunctival malignant melanoma in Sweden 1969-91. Acta Ophthalmol (Copenh) 1992 Jun;70(3):289–296. doi: 10.1111/j.1755-3768.1992.tb08566.x. [DOI] [PubMed] [Google Scholar]
  29. Stretch J. R., Gatter K. C., Ralfkiaer E., Lane D. P., Harris A. L. Expression of mutant p53 in melanoma. Cancer Res. 1991 Nov 1;51(21):5976–5979. [PubMed] [Google Scholar]
  30. Taylor C. R., Shi S. R., Chaiwun B., Young L., Imam S. A., Cote R. J. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol. 1994 Mar;25(3):263–270. doi: 10.1016/0046-8177(94)90198-8. [DOI] [PubMed] [Google Scholar]
  31. Tobal K., Warren W., Cooper C. S., McCartney A., Hungerford J., Lightman S. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer. 1992 Nov;66(5):900–904. doi: 10.1038/bjc.1992.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Vogelstein B. Cancer. A deadly inheritance. Nature. 1990 Dec 20;348(6303):681–682. doi: 10.1038/348681a0. [DOI] [PubMed] [Google Scholar]
  33. Wee A., Teh M., Raju G. C. Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions. J Clin Pathol. 1994 May;47(5):453–456. doi: 10.1136/jcp.47.5.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Weiss J., Schwechheimer K., Cavenee W. K., Herlyn M., Arden K. C. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer. 1993 Jun 19;54(4):693–699. doi: 10.1002/ijc.2910540427. [DOI] [PubMed] [Google Scholar]
  35. Wolf H. K., Dittrich K. L. Detection of proliferating cell nuclear antigen in diagnostic histopathology. J Histochem Cytochem. 1992 Sep;40(9):1269–1273. doi: 10.1177/40.9.1354677. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES